Dr Anish Kotecha summarises a study into the use of the glucagon-like peptide-1 receptor agonist semaglutide, alongside a lifestyle intervention, to reduce weight.
This site is intended for healthcare professionals
Thanks for your feedback. Please note that by including your email address, you are giving permission for us to contact you by email to help resolve any issues.
You need to register for GPnotebook Pro in order to track your activity on GPnotebook TV
You’re now logged in
Would you like to subscribe to our weekly email update containing links to the latest videos on GPnotebook TV?